Literature DB >> 12090865

Changing profile of infective endocarditis: results of a 1-year survey in France.

Bruno Hoen1, François Alla, Christine Selton-Suty, Isabelle Béguinot, Anne Bouvet, Serge Briançon, Jean-Paul Casalta, Nicolas Danchin, François Delahaye, Jerome Etienne, Vincent Le Moing, Catherine Leport, Jean-Luc Mainardi, Raymond Ruimy, François Vandenesch.   

Abstract

CONTEXT: Since the first modern clinical description of infective endocarditis (IE) at the end of the 19th century, the profile of the disease has evolved continuously, as highlighted in epidemiological studies including a French survey performed in 1991.
OBJECTIVE: To update information gained from the 1991 study on the epidemiology of IE in France. DESIGN AND
SETTING: Population-based survey conducted from January through December 1999 in all hospitals in 6 French regions representing 26% of the population (16 million inhabitants). PATIENTS: Three hundred ninety adult inpatients diagnosed with IE according to Duke criteria. MAIN OUTCOME MEASURES: Incidence of IE; proportion of patients with underlying heart disease; clinical characteristics; causative microorganisms; surgical and mortality outcomes.
RESULTS: The annual age- and sex-standardized incidence was 31 (95% confidence interval [CI], 28-35) cases per million, not including the region of New Caledonia, which had 161 (95% CI, 117-216) cases per million. There was no previously known heart disease in 47% of the cases. The proportion of prosthetic-valve IE was 16%. Causative microorganisms were: streptococci, 48% (group D streptococci, 25%; oral streptococci, 17%, pyogenic streptococci, 6%); enterococci, 8%; Abiotrophia species, 2%; staphylococci, 29%; and other or multiple pathogens, 8%. Blood cultures were negative in 9% and no microorganism was identified in 5% of the cases. Early valve surgery was performed in 49% of the patients. In-hospital mortality was 16%. Compared with 1991, this study showed a decreased incidence of IE in patients with previously known underlying heart disease (20.6 cases per million vs 15.1 cases per million; P<.001); a smaller incidence of oral streptococcal IE (7.8 cases per million vs 5.1 cases per million; P<.001), compensated by a larger proportion of IE due to group D streptococci (5.3 cases per million vs 6.2 cases per million; P =.67) and staphylococci (4.9 cases per million vs 5.7 cases per million; P =.97); an increased rate of early valve surgery (31.2% vs 49.7%; P<.001); and a decreased in-hospital mortality rate (21.6% vs 16.6%; P =.08).
CONCLUSION: Although the incidence of IE has not changed, important changes in disease characteristics, treatment, and outcomes were noted.

Entities:  

Mesh:

Year:  2002        PMID: 12090865     DOI: 10.1001/jama.288.1.75

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  199 in total

Review 1.  Injection drug use and right sided endocarditis.

Authors:  Rob Moss; Brad Munt
Journal:  Heart       Date:  2003-05       Impact factor: 5.994

Review 2.  Indications and optimal timing for surgery in infective endocarditis.

Authors:  F Delahaye; M Célard; O Roth; G de Gevigney
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

3.  A novel Streptococcus organism identified in a case of fulminant endocarditis using 16S rDNA sequencing.

Authors:  Zsolt Jobbagy; Claire B Fabian; Vincent A Memoli; Joseph D Schwartzman
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

4.  A survey on the use of gentamicin in infective endocarditis.

Authors:  G Béraud; G Le Moal; A Elsendoorn; P Tattevin; C Godet; S Alfandari; W Couet; P Roblot; F Roblot
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-29       Impact factor: 3.267

5.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

6.  Update on echocardiography in the management of infective endocarditis.

Authors:  John Francis Sedgwick; Darryl John Burstow
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 7.  [Infective endocarditis as cardiovascular emergency].

Authors:  B Plicht; R-A Jánosi; T Buck; R Erbel
Journal:  Internist (Berl)       Date:  2010-08       Impact factor: 0.743

Review 8.  Infective endocarditis: therapeutic options and indications for surgery.

Authors:  Aneil Malhotra; Jenny Rayner; Timothy M Williams; Bernard Prendergast
Journal:  Curr Cardiol Rep       Date:  2014-04       Impact factor: 2.931

9.  [Infective endocarditis : emergency treatment and long-term surveillance].

Authors:  S Dietz; H Lemm; H Bushnaq; H-P Hobbach; K Werdan; M Buerke
Journal:  Internist (Berl)       Date:  2013-01       Impact factor: 0.743

10.  NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

Authors:  Clint S Schmidt; C Jo White; Ashraf S Ibrahim; Scott G Filler; Yue Fu; Michael R Yeaman; John E Edwards; John P Hennessey
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.